Assessment of Visual Acuity in Patients With Polypoidal Choroidal Vasculopathy and Aflibercept Treatment

Sponsor
Fondation Ophtalmologique Adolphe de Rothschild
Study ID
NCT02381730
Status
Completed

Conditions

  • Polypoidal Choroidal Vasculopathy

Eligibility Criteria

Sex
ALL
Age
45 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Intravitreal aflibercept — DRUG
    Patient receive one intravitreal injection of 2mg aflibercept (as currently recommended in the treatment of AMD)

Study Details

Polypoidal choroidal vasculopathy (PCV) is a disease of the choroidal vasculature, that is often regarded as a sub-type of age-related macular degeneration (AMD). However, PCV response to anti-vascular agents differs from the response of typical AMD. This study aims at describing the evolution of the best corrected visual acuity (BCVA) in PCV patients, 28 weeks after they receive one injection of intravitreal aflibercept (2mg).

Key Dates

Start date
Jan 31, 2014
Status verified
Dec 2017
Primary completion
Aug 31, 2017
Completion
Aug 31, 2017

Study Design

Enrollment
37 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Aflibercept

Primary Outcome Measure

Evolution of the best corrected visual acuity (BCVA) measured on the EDTRS scale, between pre-injection and 28 weeks after injection [ Time Frame: 28 weeks ]

Related Studies